Recipharm invests EUR 2.6 million in Kaysersberg facility
Global contract development and manufacturing organisation (CDMO), Recipharm, has announced a EUR 2.6 million investment for additional manufacturing capacity to support increased demand into its Kaysersberg facility.
This investment in the Kaysersberg facility, located in the Alsace region of France, will add additional capacity and capabilities for the company’s customers, as the company continues to secure new business for the future.
This latest investment is part of Recipharm’s phased expansion plan for the facility. Yves Buelens, General Manager at the Kaysersberg facility, said: “It’s great to see more investment into our facility. Our sustained growth over the last few years is testament to our talented and passionate team. We continue to look for new ways to develop our offering and implement our continued growth plan, which will naturally bring more employment opportunities to the region.”
Recipharm in Kaysersberg is one of the company’s sterile manufacturing facilities. It specialises in producing sterile liquids for therapeutic areas including eye care and ear drops.
The facility has been inspected and approved by multiple regulatory agencies across the globe. It also holds a number of approvals for its environmental management systems and occupational health and safety management systems.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance